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ABSTRACT 
Introduction: Unsafe abortion is one of the main causes of maternal mortality. 
Each year, approximately 21.6 million women worldwide still undergo an unsafe 
abortion resulting in an estimated 47000 deaths. Currently 39% of the population 
lives in countries with highly restrictive abortion laws. However also in countries 
where abortion is legal, obstructive administrative procedures and insufficient 
services or providers reduce access to safe abortion services.  Medical abortion is 
one of the safest medical procedures, with minimal morbidity and a negligible 
risk of death. Task shifting may result in increased access to and availability of 
medical abortion services while maintaining the same quality of care. While task 
shifting can be done to other healthcare professionals, it can also be done to 
women themselves with the use of telemedicine.  
Material, methods and results:  
Study 1 describes the outcome of medical abortions provided via Women on 
Web, a telemedical abortion service for women with an unwanted pregnancy up 
to 9 weeks living in countries without safe abortion care. This retrospective study 
analyzed interactive web-based questionnaires, follow-up forms, emails, and 
telephone calls from 484 women who received a medical abortion at their home 
addresses. Sixteen of the 265 (6.0%) women who provided follow-up 
information reported that they did not use the medication. Of the remaining 249 
women who did the medical abortion at home, 13.6% reported having a surgical 
intervention afterwards and 1.6% reported a continuing pregnancy. After the 
follow up rate increased from 54.8% to 77.6% of the cases, 12.6% of the women 
reported they did not take the medication and only 6.8% of the women having 
the medical abortion at home underwent a surgical intervention afterwards. 
Study 2 explored the factors that influence the surgical intervention rate after 
home medical abortion provided through Women on Web to women with a 
pregnancy up to 9 weeks. Of the 2323 women who did the medical abortion, 289 
(12.4%) received a surgical intervention. High rates were found in Eastern 
Europe (14.8%), Latin America (14.4%) and Asia/Oceania (11.0%) and low 
rates in Western Europe (5.8%), the Middle East (4.7%) and Africa (6.1%; 
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p=0.000). More interventions were carried out when women had a longer 
gestational age (p=0.000). Women without a surgical intervention reported 
satisfaction with the treatment more frequently (p=0.000). 
Study 3 evaluated the need for and outcome of self-administered medical 
abortion in Brazil, provided through telemedicine. Of the 370 women used the 
medicines, 307 women provided follow-up information about the outcome of the 
medical abortion. Of this group, 207 (67.4%) of the women were up to 9 weeks 
pregnant, 71 (23.1%) were 10, 11 or 12 weeks pregnant, and 29 (9.5%) of the 
women were at least 13 weeks pregnant. There was a significant difference in 
surgical intervention rates after the medical abortion at the different gestations 
(19.3% at <9 weeks, 15.5% at 10-12 weeks and 44.8% at >13 weeks, p=0.06). 
However, 42.2% of the women who had received a surgical intervention 
afterwards did not have any symptoms of a complication. 
Study 4 assessed the efficacy, safety and acceptability of midlevel provision of 
medical abortion in a clinical high resource setting. In total 1180 women eligible 
for inclusion were recruited and randomized to either a nurse midwife or a 
gynecologist for counseling, examination including ultrasound and treatment.  
The provision of medical abortion by midlevel providers proved to be as 
effective and safe as the medical abortion provided by physicians. The risk 
difference for efficacy was 1.6%, which falls within the 5% margin that was set 
for equivalence (p=0.027). Women were significantly more likely to prefer a 
midwife for the consultation (p<0,001). 
Conclusion: The research shows that medical abortion can be safely and 
effectively provided by midlevel health care providers as well as women 
themselves through telemedicine. The acceptability and outcome of medical 
abortion up to 9 weeks of pregnancy is similar when provided by doctors, nurse 
midwives or administered by women themselves via telemedicine. Surgical 
intervention rates after the medical abortion provided via telemedicine reflect 
local medical practices. The risk of surgical intervention and ongoing pregnancy 
after home medical abortion only tends to increase after 12 weeks of pregnancy. 
 
 iii 
LIST OF SCIENTIFIC PAPERS 
 
I. 
Gomperts RJ, Jelinska K, Davies S, Gemzell-Danielsson K, Kleiverda G. 
Using telemedicine for termination of pregnancy with mifepristone and 
misoprostol in settings where there is no access to safe services. BJOG 2008 
Aug;115(9):1171-5. 
 
II. 
Gomperts R, Petow SA, Jelinska K, Steen L, Gemzell-Danielsson 
K, Kleiverda G. Regional differences in surgical intervention following 
medical termination of pregnancy provided by telemedicine. Acta Obstet 
Gynecol Scand. 2012 Feb;91(2):226-31. 
 
III. 
Gomperts R, van der Vleuten K, Jelinska K, da Costa CV, Gemzell-
Danielsson K, Kleiverda G. Provision of medical abortion 
using telemedicine in Brazil. Contraception 2014 Feb;89(2):129-33.  
 
IV. 
Kopp Kallner H, Gomperts R, Salomonsson E, Johansson M, Marions L, 
Gemzell Danielsson K. The efficacy, safety, and acceptability of medical 
abortion provided by midlevel providers or physicians in a high resource 
setting- a randomized controlled equivalence trial (submitted for publication). 
 
 
 iv 
CONTENTS 
1	   Introduction................................................................................................... 1	  
1.1	   Abortion worldwide ........................................................................... 1	  
1.1.1	   Human right to safe Abortion care........................................ 2	  
1.2	   Barriers to Access safe abortion services........................................... 3	  
1.2.1	   Countries where abortion is legal.......................................... 3	  
1.2.2	   Logistical, financial, administrative, procedural and 
geographical barriers to access abortion............................................ 4	  
1.2.3	   Gestational limits ................................................................... 7	  
1.2.4	   Conscientious objection......................................................... 7	  
1.2.5	   Restrictive abortion laws ....................................................... 8	  
1.2.6	   Religious views on abortion. ............................................... 10	  
1.2.7	   Health effects of restricted abortion access......................... 11	  
1.3	   Medical abortion: A revolution........................................................ 13	  
1.3.1	   Background.......................................................................... 13	  
1.3.2	   Mifepristone......................................................................... 15	  
1.3.3	   Misoprostol .......................................................................... 16	  
1.3.4	   Different protocols for different gestational periods........... 17	  
1.3.5	   The comparison of medical abortion to surgical abortion. . 18	  
1.3.6	   Follow up ............................................................................. 18	  
1.3.7	   Possible complications and treatment ................................. 19	  
1.3.8	   The role of Midlevel Healthcare providers ......................... 20	  
 v 
1.3.9	   The role of women themselves............................................ 21	  
1.3.10	   The promise of telemedicine ............................................... 23	  
2	   Aims of the study ........................................................................................ 26	  
3	   Material and Methods ................................................................................. 27	  
3.1	   Study subjects ................................................................................... 27	  
3.1.1	   Study 1: Outcome and acceptability of medical abortion at 
home provided via telemedicine...................................................... 27	  
3.1.2	   Study 2: Factors influencing the outcome of medical abortion 
at home provided via telemedicine .................................................. 27	  
3.1.3	   Study 3:  Medical abortion provided to women living in Brazil 
via telemedicine. .............................................................................. 27	  
3.1.4	   Study 4: Midlevel provision of medical abortion. .............. 27	  
3.1.5	   Study 5: Outcome of home medical abortions after 12 weeks 
of gestation with different misoprostol regiments........................... 28	  
3.2	   Evaluated parameters........................................................................ 28	  
3.2.1	   Study 1, 2, 3 and 5. .............................................................. 28	  
3.2.2	   Study 1: Outcome and acceptability of home medical abortion 
provided via telemedicine. ............................................................... 29	  
3.2.3	   Study 2: Factors influencing the outcome of home medical 
abortion provided via telemedicine. ................................................ 29	  
3.2.4	   Study 3: Medical abortion provided to women living in Brazil 
via telemedicine. .............................................................................. 30	  
3.2.5	   Study 4: Midlevel provision of medical abortion. .............. 31	  
3.2.6	   Study 5: Outcome of home medical abortions after 12 weeks 
gestation with different misoprostol regiments. .............................. 31	  
 vi 
3.3	   Study treatment................................................................................. 32	  
3.3.1	   Study 1, 2. ............................................................................ 32	  
3.3.2	   Study 3. ................................................................................ 33	  
3.3.3	   Study 4. ................................................................................ 33	  
3.3.4	   Study 5. ................................................................................ 34	  
3.4	   Data analyses and Statistics.............................................................. 35	  
3.4.1	   Study 1: Outcome and acceptability of home medical abortion 
provided via telemedicine................................................................ 35	  
3.4.2	   Study 2: Factors influencing the outcome of home medical 
abortion provided via telemedicine ................................................. 35	  
3.4.3	   Study 3:  Medical abortion provided to women living in Brazil 
via telemedicine. .............................................................................. 35	  
3.4.4	   Study 4: Midlevel provision of medical abortion ............... 35	  
3.4.5	   Study 5: Outcome of home medical abortions after 12 weeks 
gestation with different misoprostol regiments. .............................. 36	  
3.5	   Ethical consideration ........................................................................ 36	  
4	   Results ......................................................................................................... 37	  
4.1	   Results study 1, 2, 3 and 5: Provision of medical abortion through 
telemedice. ................................................................................................. 37	  
4.1.1	   Demographic characteristics of the women using the 
telemedical service........................................................................... 37	  
4.1.2	   Gestational age up to 9 weeks. ............................................ 38	  
4.1.3	   Gestational age of more than 9 weeks................................. 39	  
4.1.4	   Complaints and symptoms of a possible complication....... 39	  
 vii 
4.1.5	   Factors influencing surgical intervention rate. .................... 41	  
4.1.6	   Ongoing pregnancy rates. .................................................... 43	  
4.1.7	   Acceptability. ....................................................................... 44	  
4.2	   Study 4: Midwife provision of medical abortion............................. 46	  
5	   Conflict of interest. ..................................................................................... 47	  
6	   Discussion. .................................................................................................. 48	  
7	   Acknowledgements..................................................................................... 56	  
8	   References................................................................................................... 58	  
 
 viii 
LIST OF ABBREVIATIONS 
  
D&C 
D&E 
EC 
Dilatation and (sharp) Curretage 
Dilatation and Evaculation 
Emergency Contraceptives 
EUR 
FIGO 
Euro 
The International Federation of Gynaecology and Obstetrics 
HCG Human Chorionic Gonadotropin 
LMP 
PPH 
UK 
Last Mentrual Period 
Post Partum Heamorrage 
United Kingdom 
US United States 
USSR 
VA 
Union of Soviet Socialist Republics 
Vacuum Aspiration 
WHO World Health Organisation 
WoW Women on Web 
  
  
  
